Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR) in the Treatment of Generalized Anxiety Disorder (SILVER)

Trial Profile

An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR) in the Treatment of Generalized Anxiety Disorder (SILVER)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary) ; Paroxetine
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SILVER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Oct 2012 Planned number of patients changed from 800 to 805 as reported by European Clinical Trials Database record.
    • 06 Dec 2011 Results from a pooled analysis published in the Human Psychopharmacology: Clinical and Experimental.
    • 28 Jun 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM trials presented at the 9th World Congress of Biological Psychiatry.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top